Intellia, Morgan Stanley

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens
Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight,’ slashing its price target from $56 to $11. The downgrade and what the brokerage says is a broader lack of catalysts for the year dented retail sentiment,
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan Stanley
Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal weight rating in a report published on Monday morning, MarketBeat.com reports.
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now
Intellia downgraded at Morgan Stanley on lowered expectations for rare disease asset
Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran.
Morgan Stanley cuts Intellia stock rating amid gene editing concerns
Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also significantly reduced its price target to $11.
bovnews17h
Intellia Therapeutics Inc (NTLA) Posted -1212.19% Profit Margin Last Year—Can It Hold Up?
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.99 which represents a decrease of $-0.30 or -2.66% from the prior close of $11.29. The stock opened at $11.25 and touched a ...
Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
bovnews6d
What’s Driving Intellia Therapeutics Inc (NTLA) Stock’s -29.00% Plunge Over the Past Month?
Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...
news.stocktradersdaily1d
Trading (NTLA) With Integrated Risk Controls
Longer Term Trading Plans for NTLA. Buy NTLA near 10.06 target 13.33 stop loss @ 10.03 Details; The technical summary data ...
Nasdaq6d
Intellia Therapeutics Doses First Patient in Global Phase 3 Study of NTLA-2002 for Hereditary Angioedema Treatment
Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...
Morningstar5d
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...